Pharmacokinetics and Safety Study of DWJ1392 and DWC20164 in Healthy Male Volunteers

Daewoong Pharmaceutical Co. LTD.28 enrolled

Overview

The purpose of this study to Compare the safety and pharmacokinetics of DWJ1392 and DWC20164 in healthy male volunteers.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

DWJ1392DRUG

DWC20164DRUG

Eligibility

Sex: MALEMin age: 19 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * No clinically significant findings * Age 19-50 years at screening Exclusion Criteria: * Who has allergy to investigational product

Locations (1)

Seoul ST. Mary's Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

Maximum Plasma Concentration (Cmax)

Time frame: 0-72 hours

Area under the plasma concentration versus time curve (AUC)

Time frame: 0-72 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.